Drivers of disparities in stage at diagnosis among women with breast cancer: South African breast cancers and HIV outcomes cohort.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
accepted:
05
02
2023
received:
04
08
2022
entrez:
16
2
2023
medline:
25
2
2023
pubmed:
17
2
2023
Statut:
epublish
Résumé
In low- and middle-income countries (LMICs), advanced-stage diagnosis of breast cancer (BC) is common, and this contributes to poor survival. Understanding the determinants of the stage at diagnosis will aid in designing interventions to downstage disease and improve survival from BC in LMICs. Within the South African Breast Cancers and HIV Outcomes (SABCHO) cohort, we examined factors affecting the stage at diagnosis of histologically confirmed invasive breast cancer at five tertiary hospitals in South Africa (SA). The stage was assessed clinically. To examine the associations of the modifiable health system, socio-economic/household and non-modifiable individual factors, hierarchical multivariable logistic regression with odds of late-stage at diagnosis (stage III-IV), was used. The majority (59%) of the included 3497 women were diagnosed with late-stage BC disease. The effect of health system-level factors on late-stage BC diagnosis was consistent and significant even when adjusted for both socio-economic- and individual-level factors. Women diagnosed in a tertiary hospital that predominantly serves a rural population were 3 times (OR = 2.89 (95% CI: 1.40-5.97) as likely to be associated with late-stage BC diagnosis when compared to those diagnosed at a hospital that predominantly serves an urban population. Taking more than 3 months from identifying the BC problem to the first health system entry (OR = 1.66 (95% CI: 1.38-2.00)), and having luminal B (OR = 1.49 (95% CI: 1.19-1.87)) or HER2-enriched (OR = 1.64 (95% CI: 1.16-2.32)) molecular subtype as compared to luminal A, were associated with a late-stage diagnosis. Whilst having a higher socio-economic level (a wealth index of 5) reduced the probability of late-stage BC at diagnosis, (OR = 0.64 (95% CI: 0.47-0.85)). Advanced-stage diagnosis of BC among women in SA who access health services through the public health system was associated with both modifiable health system-level factors and non-modifiable individual-level factors. These may be considered as elements in interventions to reduce the time to diagnosis of breast cancer in women.
Identifiants
pubmed: 36795733
doi: 10.1371/journal.pone.0281916
pii: PONE-D-22-21910
pmc: PMC9934316
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0281916Subventions
Organisme : NCI NIH HHS
ID : R01 CA192627
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA244559
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA250012
Pays : United States
Informations de copyright
Copyright: © 2023 Mapanga et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Breast Cancer Res Treat. 2017 Feb;162(1):105-114
pubmed: 28025716
Lancet Oncol. 2013 Apr;14(4):363-70
pubmed: 23375833
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancer Epidemiol Biomarkers Prev. 2016 Apr;25(4):613-23
pubmed: 26819266
Mol Clin Oncol. 2015 Jul;3(4):785-788
pubmed: 26171180
Asian Pac J Cancer Prev. 2021 Apr 01;22(4):1007-1017
pubmed: 33906291
BMC Public Health. 2013 Oct 09;13:947
pubmed: 24107190
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
Lancet Glob Health. 2020 Sep;8(9):e1203-e1212
pubmed: 32827482
Lancet Glob Health. 2016 Dec;4(12):e923-e935
pubmed: 27855871
World J Surg Oncol. 2018 Mar 22;16(1):63
pubmed: 29566711
N Engl J Med. 2014 Oct 2;371(14):1344-53
pubmed: 25265493
Breast. 2018 Feb;37:163-169
pubmed: 29246526
BMJ Open. 2016 Jan 04;6(1):e009905
pubmed: 26729392
J Glob Oncol. 2017 Apr;3(2):114-124
pubmed: 28706996
PLoS One. 2018 Feb 2;13(2):e0192071
pubmed: 29394271
PLoS One. 2019 Mar 20;14(3):e0212806
pubmed: 30893313
J Clin Oncol. 2005 Sep 20;23(27):6639-46
pubmed: 16170171
BMJ. 2021 Feb 24;372:n256
pubmed: 33627312
PLoS Med. 2014 Sep 09;11(9):e1001720
pubmed: 25202974
Int J Cancer. 2020 Jul 15;147(2):361-374
pubmed: 31600408
J Glob Oncol. 2019 Jul;5:1-10
pubmed: 31322993
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
BMC Public Health. 2020 Mar 4;20(1):289
pubmed: 32131787
Int J Cancer. 2018 Apr 15;142(8):1568-1579
pubmed: 29197068
Cancer Causes Control. 2017 Jul;28(7):685-697
pubmed: 28447308